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Two side effects which limit the use of cisplatin in cancer chemotherapy are severe nephrotoxicity and ototoxicity. The concurrent 
administration of sodium thiosulfate with cisplatin reportedly protects from cisplatin nephrotoxicity, however. protection from 
ototoxicity has not been documented. The purpose of this study was to examine the efficacy of using thiosulfate to ameliorate the 
ototoxic effects of cisplatin. Toward this end, the effects of cisplatin alone, cisplatin administered concurrently with sodium 
thiosulfate (CIS/THIO), and sodium thiosulfate alone on the auditory brainstem response (ABR) of guinea pigs were compared. 
ABR waveforms, comparing latencies, amplitudes and response thresholds, were monitored before, immediately after, and 30 days 
post treatment. Sodium thiosulfate administered with cisplatin tCIS/THIO) consistently protected animals from hearing loss and 
surprisingly yielded significant increases in amplitude when compared to baseline and saline controls. However. ABRs of CIS/THlO 
animals returned toward baseline values after 30 days. 
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Introduction 
Cis-Diamminedichloroplatinum (II) (cisplatin) 
has been demonstrated to have antineoplastic ac- 
tivity against genitourinary cancer, (Loehrer and 
Einhorn, 1984) head and neck cancer, (Jacobs et 
al., 1978) and some lung cancers (Loehrer and 
Einhorn, 1984; Klastersky, 1985). Among its re- 
ported toxic effects are nausea, vomiting, hyper- 
uricemia, leukopenia, thrombocytopenia, and 
nephrotoxicity (Kovach et al., 1973; Strauss et al., 
1983; Loehrer and Einhorn, 1984). In addition, a 
high rate of peripheral neuropathy (Thompson et 
al., 1984; Von Hoff et al., 1979) and hearing loss 
(Kovach et al., 1973; Helson et al., 1978; McHa- 
ney et al., 1983; Strauss et al., 1983) have been 
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reported. This hearing loss has been described as 
being directly related to cumulative dose, prim- 
arily affecting the basal turns of the cochlea (Hel- 
son et al., 1978; Reddel et al., 1982). Animal 
ototoxicity studies reveal that cisplatin mainly 
damages outer hair cells (Nakai et al., 1982; 
Stadnicki et al., 1975; Fleischman et al., 1975). 
Several treatment regimens have been used to 
minimize the nephrotoxicity of cisplatin therapy 
(Higby et al., 1973; Comis, 1980; Kurebe et al., 
1985). One of the more promising regimens, used 
for treating various types of neoplasms, employs 
two-route chemotherapy, (Helson et al., 1978) 
using concurrent administration of cisplatin and 
sodium thiosulfate. Various combinations of 
two-route chemotherapy (i.e. i.p. cisplatin/i.v. 
thiosulfate, (Howell et al., 1983) i.a. cisplatin/i.v. 
thiosulfate, (Uozumi et al., 1983) i.v. cisplatin/i.v. 
sodium thiosulfate via separate sites (Pfeifle et al., 
1985) reportedly protect against nephrotoxicity 
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and, in some cases, result in enhancement of the 
anticancer effect (Howell et al., 1983; Uozumi et 
al., 1983). Thiosulfate has been described as a free 
radical scavenger. When it interacts with cisplatin 
it apparently binds covalently to produce an inac- 
tive compound. (Howell et al., 1982). 
The purpose of this study was to compare the 
effects of cisplatin alone, cisplatin administered 
concurrently with sodium thiosulfate, and sodium 
thiosulfate alone upon the auditory brainstem re- 
sponse (ABR) of guinea pigs. Latencies, ampli- 
tudes, and thresholds of ABR wave forms were 
compared. The cochleas and brains of each animal 




Fifty-six female albino guinea pigs (425-690 g) 
were used in these experiments. There was no 
evidence of middle ear pathology and all animals 
had well-formed auditory brainstem responses and 
normal thresholds before treatment began (i.e., at 
baseline). 
Auditory evoked potentials 
ABRs were recorded before drug treatment, 
two days post treatment and 30 days or more post 
drug treatment. Prior to ABR testing, each guinea 
pig was sedated with a 0.39 ml/kg mixture of 
Ketamine and Xylazine (3 mg/ml Ketalar to 1 
mg/ml Rompun). Animals were placed in a sound 
suite (Ray Proof Corp., Model AS216) during all 
recording sessions. Subdermal electrodes were in- 
serted at the vertex (active electrode), right and 
left mastoids (ipsilateral and contralateral refer- 
ences) and right elbow (ground). Stimuli were 
rarefaction clicks generated by electrical square 
waves of 50 ps presented to the right ear via an 
insert earphone (Etymotic Research, model ER-2) 
at rates of 27.1 and 77.1 clicks per s. Ipsilateral 
and contralateral responses were averaged using a 
Nicolet CA-1000 signal averager, high pass filter- 
ing at 30 Hz and low pass filtering at 3 kHz. 
Analysis time was 10 ms and sensitivity (artifact 
rejection) was set at +/-25 pv. Using a repetition 
rate of 27.1 clicks per s, 500 responses were aver- 
aged at 10 dB decrements from 91 dB peak sound 
pressure level (SPL) down to visual detection 
threshold. The repetition rate was then increased 
to 77.1 per s and responses were acquired at 81 dB 
peak SPL. Each averaged response was repeated 
to insure data reliability. 
Treatment 
Guinea pigs were divided into 5 groups. Group 
1 (CIS-8) contained 17 guinea pigs which were 
injected with i-m. cisplatin (1.5 mg/kg/day) for 8 
days. Group 2 (CIS/THIO) contained 11 guinea 
pigs which were injected with the same i.m. dose 
of cisplatin as group 1 but also given a concurrent 
dose of sodium thiosulfate, 1600 mg/kg/day i.p. 
for 8 days. Group 3 contained 10 guinea pigs 
which were injected i.m. with normal saline (1.5 
mg/kg/day) for 8 days. Group 4 (THIO) con- 
tained 6 animals which were injected i.p. with 
sodium thiosulfate (1600 mg/kg/day) for 8 days. 
Group 5 (CIS-5) contained 12 guinea pigs which 
were injected i.m. with cisplatin (1.5 mg/kg/day) 
for 5 days. Table I presents mean weights of each 
group. 
Statistical analysis 
Statistical analyses were performed using paired 
and unpaired, one-tailed Student’s t tests and 
analysis of variance in combination with the Tukey 
‘a’ studentized range statistic which tests for highly 
significant differences. (Dixon and Massey, 1969; 
Winer, 1971). The level of significance accepted 
was alpha = 0.05. However, attention was given to 
differences where P < 0.01 using the Tukey ‘a’ test 
in order to be more confident of differences among 
the various means. 
A series of one-way analyses of variance and 
studentized range statistics were performed on all 
ABR data. Between-group comparison of latency 
and amplitude on three different days for each of 
the 5 experimental groups, at 9 different intensi- 
ties generated 540 between-group tests. Within- 
group comparisons of the same data parameters 
resulted in an additional 270 tests. Presentation of 
such a mass of data in tabular form is prohibitive; 
therefore, only representative data at selected in- 




Administration of 1.5 mg/kg/day doses of 
cisplatin for 8 days (CIS-8) resulted in overt signs 
of severe toxicity. All CIS-8 animals suffered 
weight loss, diarrhea, and loss of hair. Analysis of 
variance and studentized range tests revealed a 
significant decrease in the weight of CIS-8 animals 
(Table I). All CIS-8 animals survived for 11 days, 
but by day 30, five animals had died (29% mortal- 
ity 5 of 17). 
WAVE I 
0 DAY 10 CIS-8 (N 17) 
3.5 
A DAY 10 CIS/THIO-8 (N 11) 1 0  BASELINE D Y 7 CIS-5 CONTROLS (N 13) (N 41) 
All guinea pigs were weighed at regular inter- 
vals throughout the treatment period. Table I pre- 
sents weight gain or loss for each group comparing 
the treatment period (days l-8) with the total 
time period (days l-30 + ). While the saline con- 
trol group and the CIS-5 animals steadily gained 
weight throughout, the CIS-8 and CIS/THIO-8 
animals steadily lost weight throughout the treat- 
ment and post treatment periods. According to 
the Tukey ‘a’ test, both the CIS-8 and 
CIS/THIO-8 animals had significant weight loss 
relative to saline treated controls. Weight and hair 
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TABLE I 
MEAN WEIGHT AT BASELINE AND MEAN WEIGHT 3.0 1, 
LOSS/GAIN FOR EXPERIMENTAL GROUPS 10 20 30 40 50 60 70 80 90 100 
Experi- Mean Mean weight Mean weight 
mental baseline change during change over 30 
group weight treatment f SE. days f S.E. 
(N) (N) (N) 
CIS-8 598.9 g - 34.6 k 12.1 g * * -62.0k22.5 g ** 
(17) (17) (12) 
CIS/ 593.8 g -11.1* 9.og ** -20.6*13.5 g ** 
THIO-8 (11) (11) (10) 
SALINE 537.4 g 48.6* 4.1 g 99.65 7.0 g 
(10) (10) (10) 
THIO 555.2 g -2.2? 7.2 g 11.7k19.2g 
(6) (6) (3) 
CIS-5 604.5 g 17.0* 5.0 g *# 25.2 f 6.9 g * 
(12) (12) (12) 
* = Significant difference from Saline Control P -c 0.05 (re. 
Tukey ‘a’) 
* * = Significant difference from Saline Control P -c 0.01 (re. 
Tukey ‘a’) 
* = Significant difference from CIS-8 P < 0.05 (re. Tukey 
‘a’) 
46 = Significant difference from CIS-8 P i 0.01 (re. Tukey 
‘a’) 
INTENSITY OF CLICK STIMULUS 
(DB PEAK SPL) 
Fig. 1. Wave I and Wave 111 Latency-intensity functions for 
three experimental groups. Mean latencies before treatment 
(baseline) and post treatment are plotted for comparison. 
(CIS-8 = i.m. cisplatin treatment for 8 days; CIS/THIO-8 = 
i.m. cisplatin and i.p. sodium thiosulfate treatment for 8 days; 
CIS-5 = cisplatin treatment for 5 days; Baseline controls = all 
experimental animals prior to treatment.) 
loss was less apparent for CIS/THIO-8 animals 
and one death occurred following the course of 
treatment. The THIO animals had no weight gain 
until after the treatment period. Three of the six 
animals in this group did not survive to the end of 
the experiment. These deaths were attributed to 
the thiosulfate treatment since no other contribu- 
tory factors could be identified. The only apparent 
systemic toxic effect for the CIS-5 group was a 
nonsignificant reduction in the rate of weight gain. 
x2 
Auditory findings TABLE II 
MEAN LATENCIES AND AMPLITUDES WITII SE. FOR 
ABR WAVE III AT 91 dB PEAK SPL The US-8 group. All the CIS-8 animals dis- 
played evidence of severe ototoxicity, suffering a 
40 dB or greater threshold shift from baseline; 6 
of 17 animals had no detectable ABR on day 10. 
By day 30, two of these six animals had died, but 
the four remaining animals had recovered suffi- 
ciently to measure latency at 91 dB. At day 30, the 
‘*- WAVE I 
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Fig. 2. Wave I and Wave III Amplitude-intensity functions for 
three selected experimental groups. Mean amplitudes before 
treatment (baseline) and post treatment are plotted for com- 
parison (CIS-8 = i.m. cisplatin treatment for 8 days; CIS/ 
THIO-8 = i.m. cisplatin and i.p. sodium thiosulfate treatment 
for 8 days; CISJ = cisplatin treatment for 5 days; BASELINE 
CONTROLS = aI1 experimental animals prior to treatment.) 
Note: Amplitudes for CIS-8 animals on day 10 at 71-91 dB are 
greater than 0.0 pV, but are undetectable from zero on this 
scale. 
CIS-8 (day 10) 
CIS/THIO (day 10) 
SALINE (day 10) 
THIO (day 10) 
CIS-5 (day 7) 
Latency in msec N 
4.26 f 0.20 11 
3.35 +0.02 11 
3.4450.05 10 
3.36 i 0.04 6 
3.44 + 0.03 11 
Amplitude in PV N 
CIS-day (day 10) 0.50+0.13 17 
CIS/THIO-8 (day 10) 8.56 + 0.92 11 
SALINE (day 10) 5.28 f 0.61 10 
THIO (day IO) 8.50 + 1.02 6 
CIS-5 (day 7) 5.47 + 0.82 12 
other 11 survivors continued to manifest evidence 
of severe auditory impairment. Fig. 1 presents 
mean latencies by intensity for Waves I and III 
measured on day 10. Only CIS-8 animals showed 
significant latency shifts. Fig. 2 presents mean 
amplitudes by intensity for Waves I and III mea- 
sured on day 10. 
In summary, the CIS-8 group differed from all 
other groups (at the end of their respective treat- 
ments) on the following measures: 
1. Latency Wave I CIS-8 prolonged (P i 0.01) 
Wave III CIS-8 prolonged (P < 0.01) 
2. Amplitude Wave I CIS-8 decreased (P < 0.01) 
Wave III CIS-8 decreased (P < 0.01) 
On day 10, CIS-8 animals also differed from 
their own baseline ABRs in all the categories 
listed previously. These highly significant dif- 
ferences persisted until the experiment was 
terminated (over 30 days). Table II presents mean 
latency and amplitude for Wave III of each ex- 
periment group at 91 dB peak SPL on day 10 (day 
7 for CIS-5 animals). 
The CIS/ THIO-8 group. Auditory brainstem 
responses of the CIS/THIO-8 animals demon- 
strated no shifts in threshold; but subtle, signifi- 
cant changes in latency and amplitude did occur. 
Fig. 2 illustrates that wave III amplitudes for the 
CIS/THIO-8 animals at day 10 were consistently 
x3 
TABLE III 
MEAN AMPLITUDE AND SE. FOR WAVE I OF 
CIS/THIO-8 ANIMALS (91 dB PEAK SPL) 
Day 0 Day 10 Day 30 
Amplitude in pV 8.25 + 0.39 4.91 +0.67 5.28 f 0.59 
Number of animals 11 11 10 
greater than mean baseline values. Latencies of 
the CIS/THIO-8 animals were not significantly 
different from either the saline control or THIO 
groups. 
In summary, measurements for CIS/THIO 
animals at day 10 revealed only one significant 
difference from saline control animals: 
1. Latency Wave I NS 
Wave III NS 
2. Amplitude Wave I NS 
Wave III CIS/THIO > Saline (P c 0.05) 
Table III illustrates mean amplitudes plus or 
minus their standard errors for Wave I of the 
CIS/THIO-8 animals when 91 dB stimuli were 
presented. Amplitudes at day 10 and at day 30 
were significantly decreased (P < 0.01) relative to 
baseline. Decreases in amplitude of Wave I were 
also consistently significant at other intensities. 
The THIO group. Amplitude and latencies for 
m 
the THIO animals were not significantly different 
from saline controls or animals in the CIS/THIO-8 
group, with one exception. Wave III amplitude 
was significantly greater than the saline group on 
day 10 (P < 0.05). As with CIS/THIO-8 group, 
these amplitudes returned to approximately base- 
line values by day 30. 
The US-5 group. No significant latency shifts 
occurred following CIS-5 treatment; neither within 
the group itself or in comparison with saline con- 
trols. Amplitudes of the CIS-5 animals decreased 
following treatment (P < 0.05). but only Wave III 
was significantly different from any other group 
on day 10 and day 30: 
1. Latency Wave I NS 
Wave III NS 
2. Amplitude Wave I NS 
Wave III CIS-5 < CIS/THIO P c 0.05 
Wave III CIS-5 < THIO P < 0.05 
Fig. 3 illustrates the effect of CIS-8 treatment 
regimen on the ABR of a representative guinea 
pig of that group versus its own baseline ABR. 
Fig. 4 is a similar illustration of a guinea pig in the 
CIS/THIO-8 group. The degradation of the 
waveform in the CIS-8 animal and the augmenta- 
tion of Wave III amplitude in the CIS/THIO-8 
CIS - 8 
- day 0 
-- day 10 
Fig. 3. Auditory brainstem response waveforms for a typical CIS-8 Guinea pig at baseline (prior to treatment) and on day 10 
following i.m. cisplatin treatment (1.5 mg/kg/day) for 8 days. Note diminished, distorted waveform after CIS-8 treatment. 
x4 
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Fig. 4. Auditory brainstem response waveforms for a typical CIS/THIO-8 Guinea pig at baseline (prior to treatment) and on day 10 
following i.m. cisplatin (1.5 mg/kg/day) and i.p. sodium thiosulfate (1600 mg/kg/day) treatment for 8 days. Note increased 
amplitude and decreased latency of waves I and III following cis/THIO-8 treatment. 
animal are characteristic of their respective treat- 
ment groups. These changes in waveform and 
amplitude are different from those in all other 
experimental groups and are statistically signifi- 
cant. 
Stimulus rate effect 
Responses were compared at two click rates 
(27.1/s and 77.1/s) at 81 dB peak SPL but results 
revealed no significant differences between groups 
in either latency or amplitude. Subjective evalua- 
tion of morphology did not reveal differences be- 
tween groups. 
Discussion 
From these experiments we conclude that 
sodium thiosulfate protects the auditory system 
from the major ototoxic effects of cisplatin. In 
addition, the cisplatin/ thiosulfate regimen ap- 
pears to lessen other overt signs of systemic toxic- 
ity. 
The significant increase in Wave III amplitude 
following CIS/THIO and THIO treatment 
provides an interesting topic for conjecture. 
Changes in this portion of the waveform indicate 
changes within the central auditory pathway. Per- 
haps this increase in amplitude is due to a release 
of normal efferent inhibition caused by the 
CIS/THIO combination or the thiosulfate alone. 
Perhaps there was a change in resting membrane 
potentials within the brainstem. This study was 
not designed to address that question. Since the 
wave III amplitude is normal on day 30, the 
elevated amplitude is transient and therefore 
probably associated with an acute effect of the 
drugs. The authors are presently studying effects 
of thiosulfate alone upon the ABR. 
ABR Wave I consistently diminished in ampli- 
tude following CIS/THIO treatment. Since wave 
I corresponds with the action potential of the 
VIIIth nerve, a decrease in amplitude indicates a 
decrease in function of the cochlea or the auditory 
nerve. The most parsimonious explanation of this 
finding is that cisplatin in the CIS/THIO treat- 
ment has a deleterious effect upon the cochlea, but 
far less than the same dose of cisplatin alone. 
In light of the proven benefits derived from 
cisplatin as an anticancer agent, we are encour- 
aged by our findings. Various two-route chem- 
otherapy regimens combining cisplatin and sodium 
thiosulfate have been highly successful in eliminat- 
85 
ing and reducing the size of tumors. Future inves- 
tigations are needed to further explore applica- 
tions of CIS/THIO therapy. 
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